title: American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study.
abstract: This study examined the safety and efficacy of an escalating dose (100 mg, 200 mg, 400 mg/day) of American ginseng over 6 weeks in a single-center, randomized, double-blind, placebo-controlled, crossover trial with 56 subjects with multiple sclerosis and fatigue. There were no serious adverse events but fatigue on ginseng, as assessed by the Fatigue Severity Scale, was not significantly different from fatigue on placebo.
authors.affiliation: Neurology Service and MS Center of Excellence-West, Portland VA Medical Center, Portland, OR, USA.
authors.forename: E
authors.initials: E
authors.lastname: Kim
authors.forename: M
authors.initials: M
authors.lastname: Cameron
authors.forename: J
authors.initials: J
authors.lastname: Lovera
authors.forename: L
authors.initials: L
authors.lastname: Schaben
authors.forename: D
authors.initials: D
authors.lastname: Bourdette
authors.forename: R
authors.initials: R
authors.lastname: Whitham
mesh_terms: D018592:Cross-Over Studies; D004311:Double-Blind Method; D005221:Fatigue / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications* / Q000503:physiopathology; D005894:Panax; D008517:Phytotherapy; D010865:Pilot Projects; D010936:Plant Extracts / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States
chemical_list: D010936:Plant Extracts